Allogene Therapeutics (ALLO) Operating Income (2019 - 2025)
Historic Operating Income for Allogene Therapeutics (ALLO) over the last 7 years, with Q3 2025 value amounting to -$44.9 million.
- Allogene Therapeutics' Operating Income rose 3744.11% to -$44.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$227.4 million, marking a year-over-year increase of 2364.43%. This contributed to the annual value of -$273.2 million for FY2024, which is 1664.08% up from last year.
- As of Q3 2025, Allogene Therapeutics' Operating Income stood at -$44.9 million, which was up 3744.11% from -$56.8 million recorded in Q2 2025.
- Allogene Therapeutics' 5-year Operating Income high stood at $1.7 million for Q4 2021, and its period low was -$99.1 million during Q1 2023.
- In the last 5 years, Allogene Therapeutics' Operating Income had a median value of -$71.4 million in 2024 and averaged -$67.6 million.
- As far as peak fluctuations go, Allogene Therapeutics' Operating Income skyrocketed by 10246.1% in 2021, and later plummeted by 574704.16% in 2022.
- Allogene Therapeutics' Operating Income (Quarter) stood at $1.7 million in 2021, then plummeted by 5747.04% to -$96.4 million in 2022, then increased by 11.71% to -$85.1 million in 2023, then rose by 28.93% to -$60.5 million in 2024, then grew by 25.77% to -$44.9 million in 2025.
- Its Operating Income was -$44.9 million in Q3 2025, compared to -$56.8 million in Q2 2025 and -$65.2 million in Q1 2025.